Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis

Effectiveness and Safety of JAK Inhibitors for the Treatment of Moderate-to-severe Atopic Dermatitis in a Real-life French Multicenter Adult Cohort

The aim is to assess effectiveness (EASI, SCORAD, IGA, DLQI, pruritus, sleep loss) and safety (clinical and biological adverse events) of JAK inhibitors in adults with moderate-to-severe atopic dermatitis in a real-life French multicenter retrospective cohort

Inclusion Criteria:

• Adults
• moderate to severe atopic dermatitis
• treated by JAK inhibitors between december 2020 and september 2021
• inefficiency, loss of efficiency or contra-indication of previous systemic agent, DUPILUMAB or phototherapy
• ineligibility to French ongoing clinical trials

Exclusion Criteria:

• Children
• mild atopic dermatitis
• eligibility to CICLOSPORINE, METHOTREXATE, DUPILUMAB, phototherapy
• eligibility to French ongoing clinical trials
• patients' opposition for the use of their records
• follow up <3 months